Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals. We aimed to assess the safety and effi cacy of more intensive lowering of LDL cholesterol with statin therapy.
Introduction
The Cholesterol Treatment Trialists' (CTT) Collaboration previously reported a meta-analysis 1 of individual data from 90 000 individuals in 14 randomised trials [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] of statin therapy versus control. Allocation to the statin regimens in those trials resulted in a weighted mean diff erence of about 1·0 mmol/L in LDL cholesterol and a proportional reduction of about a fi fth in major vascular events (defi ned as coronary death, non-fatal myocardial infarction, coronary revascularisation, or stroke). Observational studies show that there is a continuous positive relation between coronary disease risk and blood cholesterol concentrations, [16] [17] [18] so larger reductions in LDL cholesterol might well produce larger reductions in risk. This hypothesis is indirectly supported by the positive association identifi ed in the previous meta-analysis between the absolute reduction in LDL cholesterol in a trial and the proportional reduction in major vascular events in that trial. 1 Standard statin regimens (eg, 20-40 mg simvastatin daily) typically reduce LDL cholesterol concentrations by about a third, but regimens involving higher doses or newer, more potent statins (eg, 40-80 mg atorvastatin or 10-20 mg rosuvastatin daily) can halve LDL cholesterol. [19] [20] [21] [22] To determine whether larger reductions in LDL cholesterol safely produce further reductions in major vascular events, several trials have compared more intensive versus standard statin regimens. [23] [24] [25] [26] [27] Although their results tend to suggest further benefi t, 28 only two had signifi cant results for their primary outcome. 24, 26 The present meta-analysis of individual data from all of these trials assesses the eff ects of more intensive statin therapy more reliably than before. Several recent trials of statin therapy in patients with renal failure 29, 30 or chronic heart failure 31, 32 have not shown clear evidence of benefi t, and in our meta-analysis we also investigate those fi ndings. Moreover, we address the question of whether lowering of LDL cholesterol to very low concentrations might have adverse consequences.
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Methods
Study eligibility and outcomes
The CTT protocol was agreed before the fi rst trial results were available. 36 In this second cycle of analyses, we aimed to include all eligible trials reported by the end of 2009. Trials were eligible for inclusion if: the main eff ect of the intervention was to lower LDL cholesterol; no other diff erences in risk factor modifi cation were intended; and at least 1000 participants were to be recruited with at least 2 years' scheduled treatment duration.
Prespecifi ed outcomes were cause-specifi c mortality, major coronary event (coronary death or non-fatal myocardial infarction), coronary revascularisation (angioplasty or bypass grafting), stroke (subdivided by type), and new cancer diagnosis (subdivided by site). 36 As in the fi rst cycle of meta-analyses, 1 a major vascular event was defi ned as the fi rst occurrence of any major coronary event, coronary revascularisation, or stroke. In trials in patients with acute coronary syndrome, 23, 24 many of the revascularisation procedures had been planned before trial entry and happened soon afterwards, so the masked treatment allocation could not aff ect them. Consequently, only procedures resulting from recurrent ischaemia 23 or occurring more than 30 days after randomisation 24 (depending on the trial) were included. For the present analyses, cardiac deaths were subdivided into those probably or defi nitely due to coronary disease and those that might not have been (eg, sudden deaths or deaths attributed to arrhythmia, heart failure, or unspecifi ed cardiac causes). As a result, the 14 trials that were included in the previous report 1 now involve slightly fewer major coronary and major vascular events than they did before.
Statistical analysis
Analyses were to include all randomised patients irrespective of whether they received their allocated treatment (intention to treat). The primary meta-analyses were of the eff ects on disease event rates in each trial calculated as the logrank (o-e) and its variance (v) for fi rst events weighted by the absolute LDL cholesterol diff erence in that trial at 1 year (d mmol/L), 36 and are reported as eff ects per 1·0 mmol/L reduction in LDL cholesterol. In a meta-analysis of several trials, the log of the rate ratio per mmol/L (log RR) is calculated as S/V with variance 1/V (and hence with 95% CI of S/V±1·96/√V), where S is the sum over all trials of d (o-e) and V is the sum over all trials of d²v. (For unweighted analyses, d is omitted from these formulae.) For most subgroup analyses, the weight for a particular subgroup was the LDL cholesterol diff erence observed in the whole trial, but analyses by baseline LDL cholesterol concentration used trial-and subgroupspecifi c LDL weights. In trials comparing more versus less intensive statin therapy, the relevant baseline lipid values would be those achieved on the less intensive regimen. In three of these trials, [23] [24] [25] however, any statin therapy was stopped before randomisation, so their relevant baseline values had to be estimated by multiplying the values at the randomisation visit (ie, off statin treatment) by the mean proportional reduction observed at 1 year among those allocated the less intensive regimen. Proportional risk reductions in diff erent subgroups were compared by standard χ² tests for heterogeneity or, where appropriate, trend. To help to allow for multiple subdivisions, only summary rate ratios have 95% CIs; all other rate ratios have 99% CIs. Analyses were done with SAS version 9.1 (SAS Institute, Cary) and R version 2.11.1 (www.R-project.org).
Role of the funding sources
The funding sources had no involvement in study design, data collection, analysis, interpretation, report writing or publication. The writing committee had full access to all data and accepts full responsibility for the content of this report.
Results
For the meta-analyses of more versus less intensive statin therapy, individual participant data were available from all fi ve eligible trials: two 23, 24 in 8659 patients with acute coronary syndrome and three in 30 953 patients with stable coronary disease [25] [26] [27] (table; webappendix pp 1 and 2) . Overall, among the 39 612 participants in these fi ve trials, the weighted mean baseline LDL cholesterol concentration was estimated to be 2·53 mmol/L, the weighted mean diff erence at one year was 0·51 mmol/L, and the weighted median follow-up duration among survivors was 5·1 years (2·1 years for patients with acute coronary syndrome and 5·8 years for those with stable disease).
The previous CTT meta-analysis of statin therapy versus control involved 14 trials in 90 056 participants. 1 For this second cycle, individual participant data were available from seven more trials [29] [30] [31] [37] [38] [39] [40] of statin versus control among 39 470 participants: two in primary prevention, 37, 38 two in haemodialysis patients, 29, 30 and one each in patients with coronary disease, 39 diabetes, 40 and heart failure 31 ( 30 *Estimated with standard Kaplan-Meier methods, with patients censored at their date of death. †History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, peripheral artery disease, or heart failure (if known). ‡No known history of CHD or other vascular disease. §These three trials did not have active run-in periods; the values shown are the estimated on-treatment LDL cholesterol levels in the standard statin group. ||Median followup, baseline LDL-C, and LDL-C diff erence at 1 year weighted by trial-specifi c variances of observed logrank (o-e) for major vascular events. **Additional statin versus control trials included in this second cycle of analyses. † †Includes 382 randomised patients who were excluded from the original publication. 37 Table: Baseline characteristics and eligibility criteria of participating trials proportional risk reduction of 15% (95% CI 11-18; p<0·0001) associated with the mean 0·51 mmol/L further LDL cholesterol reduction. In comparisons between these fi ve trials, larger absolute reductions in LDL cholesterol were associated with larger proportional risk reductions (trend p=0·0004), but there was little residual variation after adjustment for LDL cholesterol diff erences (trend p=0·05). Overall, the weighted average further reduction in fi rst major vascular events was 28% (95% CI 22-34; p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol (fi gure 1), with separately signifi cant reductions in each of the major components of this composite outcome (fi gure 2).
In the updated meta-analysis of 21 trials of statin versus control, 7136 (2·8% per annum) of 64 744 participants allocated statin therapy had fi rst major vascular events versus 8934 (3·6% per annum) of 64 782 allocated control (fi gure 1), corresponding to a highly signifi cant 22% (95% CI 19-24; p<0·0001) risk reduction with a 1·07 mmol/L LDL cholesterol reduction. In comparisons between these 21 trials, larger absolute reductions in LDL cholesterol were 
0·72 (0·66−0·78) p<0·0001
Unweighted RR (CI)
0·78 (0·76−0·81) p<0·0001
Trend: χ 2 1 =32·3 (p<0·0001) associated with larger proportional reductions in risk (trend p<0·0001), but no signifi cant residual variation remained after adjustment for LDL cholesterol diff erences (trend p=0·4). Overall, the weighted average reduction in major vascular events was 21% (95% CI 19-23; p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol (fi gures 1 and 2). After diff erences in the absolute reductions in LDL cholesterol were accounted for, the proportional reduction in the incidence of major vascular events per mmol/L was slightly larger (heterogeneity p=0·03; fi gure 1) in the trials of more versus less intensive therapy than in those of statin versus control. Taking all 26 trials together, the risk reduction was 22% (95% CI 20-24; p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol at 1 year, with a signifi cant 12% reduction during the fi rst year after randomisation (p<0·0001) and highly signifi cant reductions of about a quarter during each subsequent year (all p<0·0001; webappendix p 3).
0·85 (0·82−0·89) p<0·0001
First major coronary events were recorded in the fi ve trials of more versus less intensive statin therapy in 1725 (1·9% per annum) participants allocated more intensive versus 1973 (2·2% per annum) allocated less intensive therapy (fi gure 2). This highly signifi cant further risk reduction of 13% (95% CI 7-19; p<0·0001) represented a signifi cant reduction in non-fatal myocardial infarction of 15% (99% CI 6-24; p<0·0001) and a non-signifi cant reduction in coronary death of 7% (p=0·2). The 
Control/less better Statin/more better Control/less better Statin/more better proportional reduction in the incidence of major coronary events per 1·0 mmol/L LDL cholesterol reduction was similar (heterogeneity p=0·8; fi gure 2; webappendix p 4) in the trials of more versus less intensive therapy (26% reduction, 95% CI 15-35) and in those of statin versus control (24%, 95% CI 21-27). Taking all 26 trials together, the risk reduction was 24% (95% CI 22-27; p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol, with highly signifi cant reductions in non-fatal myocardial infarction of 27% (95% CI 23-30; p<0·0001; webappendix p 5) and in coronary death of 20% (95% CI 15-25; p<0·0001; webappendix p 6).
First coronary revascularisation procedures were recorded in the fi ve trials of more versus less intensive statin therapy in 2250 (2·6% per annum) participants allocated more intensive versus 2741 (3·2% per annum) allocated less intensive therapy (fi gure 2). This highly signifi cant further risk reduction of 19% (95% CI 15-24; p<0·0001) represented signifi cant reductions in coronary artery surgery of 14% (99% CI 1-25; p=0·005) and in coronary angioplasty of 24% (99% CI 16-31; p<0·0001). The proportional reduction in the incidence of coronary revascularisation per 1·0 mmol/L reduction in LDL cholesterol was signifi cantly larger (heterogeneity p=0·01; fi gure 2; webappendix p 7) in the trials of more versus less intensive therapy (34% reduction, 95% CI 27-40) than in those of statin versus control (24%, 95% . This signifi cant heterogeneity refl ected a larger eff ect on coronary angioplasty and accounted for the observed diff erence between these groups of trials in the proportional reduction in major vascular events. Taking all 26 trials together, the risk reduction was 25% (95% CI 22-28; p<0·0001; webappendix p 7) per 1·0 mmol/L reduction in LDL cholesterol, with similar reductions in coronary artery surgery (25%, 99% CI 18-31) and in coronary angioplasty (28%, 99% .
First strokes of any type were recorded in the fi ve trials of more versus less intensive statin therapy in 572 (0·6% per annum) participants allocated more intensive versus 663 (0·7% per annum) allocated less intensive therapy (fi gure 2). This signifi cant further risk reduction of 14% (95% CI 4-23; p=0·009) represented a 16% (99% CI 1-29) reduction in the risk of ischaemic stroke (440 vs 526; risk ratio [RR] 0·84, 99% CI 0·71-0·99; p=0·005) and a non-signifi cant excess of haemorrhagic stroke (69 vs 57; RR 1·21, 99% CI 0·76-1·91; p=0·3). The proportional reduction in the incidence of stroke per 1·0 mmol/L LDL cholesterol reduction was nonsignifi cantly larger (heterogeneity p=0·2; fi gure 2; webappendix p 8) in the trials of more versus less intensive statin therapy (26% reduction, 95% CI 8-41) than in those of statin versus control (15% reduction, 95% CI [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Taking all 26 trials together, the risk reduction was 16% (95% CI 11-21; p<0·0001; webappendix p 8) per 1·0 mmol/L LDL cholesterol reduction, with a highly signifi cant reduction in ischaemic stroke (1427 vs 1751; RR 0·79, 95% CI 0·74-0·85; p<0·0001; webappendix p 9) and a nonsignifi cant excess of haemorrhagic stroke (257 vs 220; RR 1·12, 95% CI 0·93-1·35; p=0·2; webappendix p 10).
The outcome of fi rst stroke after randomisation was available from 24 of the 26 trials, with 728 (15%) of 4948 fi rst strokes classifi ed as fatal and a further 256 stroke deaths reported (253 after non-fatal fi rst strokes and three in a trial 9 without stroke incidence data). Overall, there was no signifi cant eff ect on mortality from 
Events (% per annum)
Statin/more Control/less 99% or 95% CI stroke (483 statin/more statin vs 501 control/less statin; RR 0·96, 95% CI 0·84-1·09; p=0·5), on mortality from fi rst stroke (369 vs 359), or on mortality from fi rst ischaemic (136 vs 124) or fi rst haemorrhagic (94 vs 75) stroke. Likewise, there was no signifi cant eff ect on the incidence of fi rst non-fatal haemorrhagic stroke (163 vs 145; RR 1·05, 99% CI 0·77-1·43; p=0·7). There was, however, a highly signifi cant reduction in fi rst nonfatal ischaemic stroke (1291 vs 1627), corresponding to a 23% (99% CI 15-30; p<0·0001) reduction per 1·0 mmol/L reduction in LDL cholesterol.
First major vascular events were reduced by about a fi fth per 1·0 mmol/L LDL cholesterol reduction in each subgroup examined in the fi ve trials of more versus less intensive statin therapy (webappendix p 11), in the 21 trials of statin versus control (webappendix p 12), and in all 26 trials combined (fi gure 3), even though the annual event rates in control groups diff ered substantially according to participants' medical history and other characteristics. In particular, there was a highly signifi cant proportional risk reduction of 25% (99% CI 18-31; p<0·0001) per 1·0 mmol/L reduction in LDL cholesterol in participants with no previous history of vascular disease, as well as signifi cant reductions of 17% (99% CI 10-24; p<0·0001) among women and of 16% (99% CI 3-27; p=0·002) in people older than 75 years at entry (fi gure 3).
Baseline LDL cholesterol concentrations were substantially higher in the trials of statin versus control (3·70 mmol/L on no statin) than in those of more versus less intensive therapy (2·53 mmol/L on the less intensive regimen), so the latter group provides most of the information about the eff ects of reducing LDL cholesterol concentrations that were already low (eg, less than 2·5 mmol/L; fi gure 4). In these trials of more versus less statin, the RR per 1·0 mmol/L further reduction in LDL cholesterol did not depend on the baseline LDL cholesterol concentration (trend p=0·2; fi gure 4), with signifi cant reductions of 23% (99% CI 6-36; p=0·0005) in participants who had LDL cholesterol of 2·0-2·5 mmol/L reduced further and of 29% (99% CI 2-48; p=0·007) in those who had LDL cholesterol lower than 2·0 mmol/L (mean 1·71 mmol/L) reduced further. Indeed, even among those reaching 1·8 mmol/L (70 mg/dL) or lower with a standard statin regimen, further reduction yielded defi nite benefi t (RR 0·63, 99% CI 0·41-0·95; p=0·004; not shown separately in fi gure 4).
Some have suggested that HDL cholesterol concentrations might not be inversely associated with vascular disease risk when LDL cholesterol is reduced intensively 42 (which would imply that the risk reduction with statin therapy is smaller in people with higher HDL cholesterol). But, this hypothesis was not supported by comparisons of the major vascular event risks in baseline HDL cholesterol subgroups (fi gure 3; webappendix pp 11 and 12). In particular, after adjustment for other risk factors, the risk ratio for upper versus lower tertiles of HDL cholesterol in participants allocated more intensive statin therapy (RR 0·81, 95% CI 0·74-0·89) was similar to that in those allocated less intensive therapy (RR 0·84, 95% CI 0·77-0·92).
Death was recorded for 3593 participants in the fi ve trials of more versus less intensive statin therapy and for 12 376 in the 21 trials of statin versus control, yielding a total of 15 969 deaths in all 26 trials. Overall, 9014 (56%) of these deaths were attributed to vascular causes (4168 coronary, 3049 other cardiac, 984 stroke, 813 other vascular), 5937 (37%) were attributed to non-vascular causes (3579 cancer, 461 respiratory, 254 trauma, and 1643 other), and 1018 (6%) had unknown causes (webappendix p 2). For each of these categories of death, the proportional reductions in risk per 1·0 mmol/L LDL cholesterol reduction did not diff er between the two types of trial comparison (all heterogeneity p values >0·1). Taking all 26 trials together, there was a proportional reduction in allcause mortality of 10% (95% CI 7-13; p<0·0001; fi gure 5) per 1·0 mmol/L reduction in LDL cholesterol, which consisted of a highly signifi cant reduction in vascular mortality of 14% (95% CI 10-18; p<0·0001) and a marginally signifi cant reduction in mortality from unknown causes of 13% (95% CI 1-24; p=0·04), with no apparent eff ect on non-vascular mortality (RR 0·97, 95% CI 0·92-1·03; p=0·3). The reduction in vascular mortality was chiefl y attributable to signifi cant reductions in deaths due to 
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Statin/more Control/less Control/less better Statin/more better 99% or 95% CI coronary disease of 20% (99% CI 13-26; p<0·0001) and other cardiac causes of 11% (99% CI 2-19; p=0·002) per 1·0 mmol/L, with no apparent eff ects on deaths due to stroke (RR 0·96, 95% CI 0·84-1·09; p=0·5) or other vascular causes (RR 0·98, 99% CI 0·81-1·18; p=0·8). With respect to non-vascular mortality, there were no apparent eff ects on deaths from cancer (RR 0·99, 99% CI 0·91-1·09), respiratory disease (RR 0·88, 99% CI 0·70-1·11), trauma (RR 0·98, 99% CI 0·70-1·38), or all other non-vascular causes (RR 0·96, 99% CI 0·83-1·10). There was no indication that reduction of LDL cholesterol in individuals with lower baseline concentrations increased non-vascular mortality (trend p=0·2).
First cancers after randomisation were recorded in 2938 participants in the fi ve trials of more versus less intensive statin therapy and in 7186 participants in the 21 trials of statin versus control, yielding a total of 10 124 fi rst cancers in all 26 trials (excluding cancers known to be recurrences of primary tumours diagnosed before randomisation, and non-melanoma skin cancers since they were not recorded routinely). In the fi ve trials of more versus less intensive statin therapy, reduction of LDL cholesterol to a mean of about 2 mmol/L had no signifi cant eff ect on the incidence of cancer at all sites combined (RR 1·02 per 1·0 mmol/L LDL cholesterol reduction, 95% CI 0·89-1·18; p=0·8) or at any particular site (fi gure 6 and webappendix p 13). Similarly, there was no signifi cant eff ect in the 21 trials of statin versus control and, taking all 26 trials together, there was no evidence of an excess of cancer at all sites combined (RR 1·00 per 1·0 mmol/L LDL reduction, 95% CI 0·96-1·04; p=0·9) or at any particular site. There was also no indication that reduction of LDL cholesterol in individuals with lower baseline concentrations increased cancer incidence (indeed, if anything, the opposite pattern was observed; trend p=0·1).
Only cases of myopathy that had progressed to rhabdomyolysis were sought from the individual trials. Overall, the observed excess of rhabdomyolysis was 4 (SE 2) per 10 000 in the fi ve trials of more versus less intensive statin therapy (14 vs six cases) compared with 1 (SE 1) per 10 000 in the 21 trials of standard statin regimens versus control (14 vs nine cases). All of the excess (ten vs no cases) with more intensive therapy occurred in the two trials of 80 mg versus 20 mg simvastatin daily; these two trials have also reported defi nite excesses in the incidence of myopathy with 80 mg simvastatin daily.
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Discussion
The previous CTT meta-analysis of individual participant data from randomised trials showed that lowering of LDL cholesterol by about 1 mmol/L with standard statin regimens safely reduced the 5-year incidence of major coronary events, revascularisations, and ischaemic strokes by about a fi fth. 1 Several trials have since directly compared more intensive versus standard statin regimens. [23] [24] [25] [26] [27] This updated meta-analysis has shown that additional reductions in LDL cholesterol (down to about 1-2 mmol/L) with more intensive therapy further reduce the incidence of these major vascular events, that the relation between absolute LDL cholesterol reductions and proportional risk reductions is consistent between the trials of more versus less intensive statin therapy and those of standard statin regimens versus control, and that these further reductions in vascular risk can be achieved safely even in individuals with low LDL cholesterol concentrations. Only two 24, 26 of the fi ve trials that assessed the eff ects of reducing LDL cholesterol more intensively [23] [24] [25] [26] [27] produced separately signifi cant results. But, adjustment for the absolute reduction in LDL cholesterol indicates that the results of these fi ve trials are compatible with one another. Overall, a further reduction in LDL cholesterol of about 0·5 mmol/L was achieved, which reduced the residual risk of major vascular events by about a sixth, with separately signifi cant reductions in coronary death or non-fatal myocardial infarction (p<0·0001), in coronary revascularisation procedures (p<0·0001), and in ischaemic stroke (p=0·005). Moreover, the proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol was similar to that observed in the updated meta-analysis of trials of statin versus control. The previous meta-analysis of statin versus control involved comparatively few major vascular events in participants with low LDL cholesterol before treatment, 1 whereas the present meta-analyses provide good evidence of benefi t, with no evidence of any hazard, even when LDL cholesterol concentrations lower than 2 mmol/L are reduced further. Overall, there was a 22% proportional reduction in the risk of major vascular events for each 1 mmol/L reduction in LDL cholesterol, which implies that, at least within the range of LDL cholesterol studied to date, a 2 mmol/L reduction would reduce the risk by about 40% (since the combination of risk ratios of 0·78×0·78 yields a risk ratio of about 0·6), and a 3 mmol/L reduction could reduce the risk by about 50%.
In the combined meta-analysis of trials of more versus less intensive statin therapy and of statin therapy versus control, coronary mortality was reduced by about a fi fth per 1·0 mmol/L LDL cholesterol reduction, but the reduction in cardiac deaths that were not attributed to coronary disease was only about half as large. This fi nding may refl ect a relative lack of benefi t from lowering of LDL cholesterol on cardiac deaths that are mediated by nonocclusive mechanisms. For example, in the GISSI-HF 31 trial of rosuvastatin versus placebo in patients with heart failure (which was included in this meta-analysis), as well as in the similar CORONA 32 trial (which was not), most cardiac deaths were non-occlusive and there were no signifi cant reductions in cardiac mortality. Nor were there signifi cant reductions in cardiac mortality in the two statin trials among patients with renal disease, 29, 30 in which only about half of cardiac deaths were defi nitely due to coronary disease. By contrast, since most of the cardiac deaths that were coded as non-coronary in this meta-analysis occurred in patients with pre-existing coronary disease, some are likely to have been due to coronary occlusion (and, hence, reduced by statin therapy). These fi ndings suggest that the absolute reduction in cardiac mortality produced by lowering of LDL cholesterol with statin therapy in a given population depends chiefl y on the absolute risk of death due to coronary occlusion.
There was no signifi cant evidence in the meta-analysis of trials of more versus less intensive therapy that further lowering of LDL cholesterol (weighted mean of 2·5 mmol/L reduced to 2·0 mmol/L) produced any adverse eff ects, even in participants with baseline LDL cholesterol lower than 2·0 mmol/L. In one of those trials, the mean LDL cholesterol was reduced from 2·5 mmol/L to 1·9 mmol/L, and there was a non-signifi cant excess of death from non-vascular or unknown causes (158 on 80 mg atorvastatin vs 127 on 10 mg atorvastatin daily; p=0·06). 25 But, that adverse trend was not supported by larger numbers of such deaths (590 [4·0%] vs 612 [4·1%]; RR 0·96, 95% CI 0·86-1·08; p=0·5) in the four other trials, or by an excess of any particular type of non-vascular mortality. Nor were there any adverse eff ects on cancer incidence in the meta-analyses of more versus less intensive therapy or of statin versus control. If lowering of LDL cholesterol with statin therapy was carcinogenic then it might be expected to increase the incidence of cancer at some particular site, and previous reports from individual trials had raised such concerns about breast 4 and gastrointestinal cancers; 11 there was, however, no evidence in our analyses of an increase in cancer at these or any other sites.
Previous observational studies have generated the hypothesis that low cholesterol concentrations might be associated with an increased risk of intracerebral haemorrhage. 18, 43, 44 The present meta-analyses, which included nearly 500 confi rmed haemorrhagic strokes, showed that lowering of LDL cholesterol with statin therapy was associated with a non-signifi cant excess (257 vs 220; p=0·2: webappendix p 10). In the SPARCL trial 33 of atorvastatin versus placebo in patients with previous cerebrovascular disease (which was not available for this meta-analysis), there was a signifi cant 20% proportional reduction in major vascular events (RR 0·80, 95% CI 0·69-0·92; p=0·002). This result included a signifi cant reduction in ischaemic stroke (218 vs 274; Control/less better Statin/more better p=0·008), but a signifi cant excess of haemorrhagic stroke (55 vs 33; p=0·02). In the two other trials of statin versus control that were not available for the meta-analysis, there were 15 versus nine haemorrhagic strokes in CORONA, 32 but the numbers were not available for GREACE. 41 If the published data for haemorrhagic stroke from SPARCL and CORONA were combined with the present meta-analysis then the rate ratio would be 1·21 (95% CI 1·05-1·41) per 1·0 mmol/L LDL cholesterol reduction. Although this result is signifi cant (p=0·01), the absolute size of the potential hazard would be about 50 times smaller (perhaps a few extra haemorrhagic strokes annually per 10 000 treated) than the defi nite absolute benefi ts (a few hundred occlusive events avoided annually per 10 000 treated) for patients who are at high risk of occlusive vascular events.
In these meta-analyses, the size of the proportional reduction in major vascular events is directly proportional to the absolute LDL reduction that is achieved, with further benefi t from more intensive statin therapy, even if LDL cholesterol is already lower than 2·0 mmol/L. Each 1 mmol/L LDL cholesterol reduction reduces the risk of occlusive vascular events by about a fi fth, irrespective of baseline cholesterol concentration, which implies that a 2-3 mmol/L reduction would reduce risk by about 40-50%. These fi ndings suggest that the primary goal for patients at high risk of occlusive vascular events should be to achieve the largest LDL cholesterol reduction possible without materially increasing myopathy risk. Current therapeutic guidelines tend to emphasise the need to reach a particular LDL cholesterol target-for example, US National Cholesterol Education Program guidelines suggest that the objective in high-risk patients should generally be to reduce LDL cholesterol to below 100 mg/dL (2·6 mmol/L) or, optionally, for very high risk patients, to below 70 mg/dL (1·8 mmol/L). 45 By contrast, our results suggest that lowering of LDL cholesterol further in high-risk patients who achieve such targets would produce additional benefi ts, without an increased risk of cancer or non-vascular mortality. Guidelines have proposed that high doses of generic statins (eg, 80 mg simvastatin daily) be used to achieve these benefi ts, 46 but such regimens may be associated with higher risk of myopathy. 27 Instead, these benefi ts may be achieved more safely with newer, more potent statins (eg, 80 mg atorvastatin or 20 mg rosuvastatin daily) and, potentially, by combination of standard doses of generic statins (eg, 40 mg simvastatin or pravastatin daily) with other LDLcholesterol-lowering therapies.
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